NewsMarkets

Business

Moderna Shares Fall After Leaked Melanoma Vaccine Data Misses High Expectations

Stocks dropped after early data showed the Moderna-Merck vaccine reduced recurrence risk by 58%, falling short of Wall Street's higher projections.

7 publishers · 13 articles · first seen 21 Oct 2026 · updated 15d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

7 publishers have covered this in 13 articles since 21 Oct 2026. MarketWatch published first, on 21 October at 15:00 UTC; STAT followed 22h 35m later. The most recent article, from Bloomberg Markets, appeared on 23 October at 19:58 UTC.

Outlets reporting it: CNBC (major outlet), Bloomberg Markets (major outlet), News Feed (major outlet), Nature (major outlet), MarketWatch, STAT, Scientific American.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

How it unfolded

Every source in the order it published.

  1. MarketWatchModerna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
  2. STATSTAT+: What to expect from the Moderna-Merck cancer vaccine data reveal
  3. MarketWatchModerna’s stock tumbles after reported leak of data for cancer vaccine
  4. STATSTAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
  5. CNBCModerna shares plunge after leak of cancer vaccine data despite positive results
  6. Bloomberg MarketsModerna, Merck Fall After Melanoma Data Leak
  7. News FeedModerna shares sink after leaked cancer data missed expectations
  8. Bloomberg.comAI Jitters, Treasuries Rally, Moderna-Merck Cancer Data Leak
  9. Scientific AmericanHere’s what Moderna’s latest mRNA cancer vaccine data actually show
  10. NatureModerna mRNA vaccine almost halves the risk of skin cancer returning
  11. Show 3 later sources
    1. MarketWatchThe real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
    2. STATSTAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
    3. Bloomberg MarketsOncologists Cheer Melanoma Data

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Oncologists Cheer Melanoma Data Bloomberg Markets ·
  2. Moderna mRNA vaccine almost halves the risk of skin cancer returning Nature ·
  3. AI Jitters, Treasuries Rally, Moderna-Merck Cancer Data Leak Bloomberg.com ·
  4. Moderna shares sink after leaked cancer data missed expectations News Feed ·
  5. Moderna, Merck Fall After Melanoma Data Leak Bloomberg Markets ·
  6. Moderna shares plunge after leak of cancer vaccine data despite positive results CNBC ·
Show 7 more sources
  1. STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early STAT
  2. The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term. MarketWatch
  3. Here’s what Moderna’s latest mRNA cancer vaccine data actually show Scientific American
  4. STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial STAT
  5. Moderna’s stock tumbles after reported leak of data for cancer vaccine MarketWatch
  6. STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal STAT
  7. Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data. MarketWatch

In this story

  • Moderna
  • Merck
Embed this story

Paste this into any web page to show the live odds, with a link back here.